Could knee inflammatory synovitis be induced by pembrolizumab?

Related Articles

Could knee inflammatory synovitis be induced by pembrolizumab?

J Oncol Pharm Pract. 2017 Jan 01;:1078155217701292

Authors: Mahmoud F, Wilkinson JT, Gizinski A, Viswamitra S, Gokden N, Vander Schilden J

Abstract
Pembrolizumab, a selective anti-PD-1 humanized monoclonal antibody, reactivates T cells to fight cancer. Immune-related adverse events such as autoimmune colitis, pneumonitis, hepatitis, nephritis, hypophysitis, and thyroiditis may occur during, or weeks to months after therapy. Pemprolizumab-induced synovitis is rarely reported. With the wide use of immunotherapy to treat cancers, physicians need to be aware of this rare immune-related adverse event and provide immediate treatment to avoid permanent joint damage.

PMID: 28355971 [PubMed - as supplied by publisher]

http://ift.tt/2nRNoi5